Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 816 (ZNF816) is a transcription factor encoded by the ZNF816 gene on human chromosome 19q13.41[1][4][5]. It contains a Krüppel-associated box (KRAB) domain and an array of 15 C2H2 zinc finger motifs, enabling it to bind DNA and repress transcription by recruiting co-repressors that promote heterochromatin formation[1][2][3]. ZNF816 is broadly expressed in many human tissues, localizes predominantly in the nucleus, and interacts with other proteins involved in transcriptional regulation, protein ubiquitination, and DNA repair (e.g., TRIM28, CUL3)[1]. While direct associations with specific diseases remain under study, ZNF816 variants have been implicated as candidates in emphysema, Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, and early-onset psoriasis[1]. No drugs are currently known to interact directly with ZNF816, nor is it established as a recognized therapeutic target[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 816 (ZNF816).